Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Avenue Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 11 | 14 | +3 |
| Shares | 75.9K | 448.9K | +372.9K (+491.2%) |
| Value | $766.0K | $520.5K | −$245.5K (−32.1%) |
New holders (7)
Institutions that held Avenue Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 264,000 | $306.2K | 0.82% |
| Bank of New York Mellon Corp | 53,363 | $61.9K | 0.00% |
| Qube Research & Technologies Ltd | 47,400 | $55.0K | 0.00% |
| Virtu Financial LLC | 32,570 | $38.0K | 0.01% |
| Geode Capital Management, LLC | 11,534 | $13.0K | 0.00% |
| Bayesian Capital Management, LP | 11,000 | $12.8K | 0.00% |
| Royal Bank of Canada | 55 | $0 | 0.00% |
Sold out (4)
Institutions that held Avenue Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Citadel Advisors LLC | 35,865 | $362.0K |
| Two Sigma Investments, LP | 14,342 | $145.0K |
| Two Sigma Securities, LLC | 14,159 | $143.0K |
| Tower Research Capital LLC (TRC) | 1,425 | $14.0K |